Elidel
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mild to Moderate Atopic Dermatitis
Conditions
Mild to Moderate Atopic Dermatitis
Trial Timeline
Dec 1, 2007 → Sep 1, 2008
NCT ID
NCT00568412About Elidel
Elidel is a approved stage product being developed by Bayer for Mild to Moderate Atopic Dermatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00568412. Target conditions include Mild to Moderate Atopic Dermatitis.
What happened to similar drugs?
7 of 16 similar drugs in Mild to Moderate Atopic Dermatitis were approved
Approved (7) Terminated (2) Active (8)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00568412 | Approved | Completed |
Competing Products
20 competing products in Mild to Moderate Atopic Dermatitis